The second license agreement provides GSK with access to BioWa’s Complegent Technology for enhancing the complement-dependent cytotoxicity (CDC) of select GSK therapeutic antibodies. These two technologies may be used in a complementary or independent approach.
As per the terms of the license agreements, BioWa grants GSK non-exclusive rights to research, develop and commercialise therapeutic antibodies generated through Potelligent and Complegent Technologies for an undisclosed number of targets.
In return, BioWa is expected to receive upfront and annual fees, development milestone payments and royalties on products.
Masamichi Koike, president and CEO of BioWa, said: “We are very pleased about our expanded partnership with GSK. We are confident that these technologies will contribute materially to GSK’s efforts in monoclonal antibody based therapeutics.”